Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
- D'Alto, Michele
- Romeo, Emanuele
- Argiento, Paola
- Santoro, Giuseppe
- Sarubbi, Berardo
- Gaio, Giampiero
- Melot, Christian
- Russo, Maria Giovanna
- Naeije, Robert
- Calabrò, Raffaele
Publication date
September 2010
DOI Publisher
BMJ ISSN
1355-6037 Citation count (estimate)
27Abstract
Vasoreactivity testing is recommended in the management of pulmonary arterial hypertension (PAH), but its clinical relevance in congenital heart disease (CHD)-associated PAH has not been established.Journal ArticleSCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG